Journal article
Incidence of diabetes mellitus following hospitalisation for COVID-19 in the United Kingdom: a prospective observational study
- Abstract:
-
Background
People hospitalised for coronavirus disease 2019 (COVID-19) have elevated incidence of diabetes. However, it is unclear whether this is due to shared risk factors, confounding or stress hyperglycaemia in response to acute illness.
MethodsWe analysed a multicentre prospective cohort study (PHOSP-COVID) of people ≥18 years discharged from NHS hospitals across the United Kingdom following COVID-19. Individuals were included if they attended at least one research visit with a HbA1c measurement within 14 months of discharge and had no history of diabetes at baseline. The primary outcome was new onset diabetes (any type), as defined by a first glycated haemoglobin (HbA1c) measurement ≥6.5% (≥48 mmol/mol). Follow-up was censored at the last HbA1c measurement. Age-standardised incidence rates and incidence rate ratios (adjusted for age, sex, ethnicity, length of hospital stay, body mass index, smoking, physical activity, deprivation, hypertension, hyperlipidaemia/hypercholesterolaemia, intensive therapy unit admission, invasive mechanical ventilation, corticosteroid use and C-reactive protein score) were calculated using Poisson regression. Incidence rates were compared with the control groups of published clinical trials in the United Kingdom by applying the same inclusion and exclusion criteria, where possible.
ResultsIncidence of diabetes was 91.4 per 1000 person-years and was higher in South Asian (incidence rate ratios [IRR] = 3.60; 1.77, 7.32; p < 0.001) and Black ethnic groups (IRR = 2.36; 1.07, 5.21; p = 0.03) compared with White ethnic groups. When restricted to similar characteristics, the incidence rates were similar to those in UK clinical trials data.
ConclusionDiabetes incidence following hospitalisation for COVID-19 is high, but it remains uncertain whether it is disproportionately higher than pre-pandemic levels.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 1.1MB, Terms of use)
-
- Publisher copy:
- 10.1111/dom.16071
Authors
- Funder identifier:
- https://ror.org/02wdwnk04
- Grant:
- CH/F/21/90010
- Funder identifier:
- https://ror.org/03x94j517
- Grant:
- MC_UU_00008/5
- MC_UU_00036/2
- MC_PC_20002
- Funder identifier:
- https://ror.org/001aqnf71
- Grant:
- MR/V027859/1
- Funder identifier:
- https://ror.org/0187kwz08
- Grant:
- NIHR203691
- Publisher:
- Wiley
- Journal:
- Diabetes, Obesity and Metabolism: A Journal of Pharmacology and Therapeutics More from this journal
- Volume:
- 27
- Issue:
- 2
- Pages:
- 767-776
- Place of publication:
- England
- Publication date:
- 2024-11-20
- Acceptance date:
- 2024-11-03
- DOI:
- EISSN:
-
1463-1326
- ISSN:
-
1462-8902
- Pmid:
-
39563623
- Language:
-
English
- Keywords:
- Pubs id:
-
2064418
- Local pid:
-
pubs:2064418
- Deposit date:
-
2025-05-14
- ARK identifier:
Terms of use
- Copyright holder:
- Tyrer et al
- Copyright date:
- 2025
- Rights statement:
- © 2024 The Author(s). Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record